166 related articles for article (PubMed ID: 26400835)
1. Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.
Jacobs P; Ang A; Hillhouse MP; Saxon AJ; Nielsen S; Wakim PG; Mai BE; Mooney LJ; S Potter J; Blaine JD
Am J Addict; 2015 Oct; 24(7):667-75. PubMed ID: 26400835
[TBL] [Abstract][Full Text] [Related]
2. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
[TBL] [Abstract][Full Text] [Related]
3. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
4. Buprenorphine alone or with naloxone: Which is safer?
Kelty E; Cumming C; Troeung L; Hulse G
J Psychopharmacol; 2018 Mar; 32(3):344-352. PubMed ID: 29433352
[TBL] [Abstract][Full Text] [Related]
5. The relationship between primary prescription opioid and buprenorphine-naloxone induction outcomes in a prescription opioid dependent sample.
Nielsen S; Hillhouse M; Weiss RD; Mooney L; Sharpe Potter J; Lee J; Gourevitch MN; Ling W
Am J Addict; 2014; 23(4):343-8. PubMed ID: 24112096
[TBL] [Abstract][Full Text] [Related]
6. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.
Ruglass LM; Scodes J; Pavlicova M; Campbell ANC; Fitzpatrick S; Barbosa-Leiker C; Burlew K; Greenfield SF; Rotrosen J; Nunes EV
Drug Alcohol Depend; 2019 Dec; 205():107649. PubMed ID: 31704382
[TBL] [Abstract][Full Text] [Related]
7. Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study.
Bakouni H; McAnulty C; Tatar O; Socias ME; Le Foll B; Lim R; Ahamad K; Jutras-Aswad D;
Am J Addict; 2023 Sep; 32(5):469-478. PubMed ID: 37308805
[TBL] [Abstract][Full Text] [Related]
8. Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.
Comer SD; Mannelli P; Alam D; Douaihy A; Nangia N; Akerman SC; Zavod A; Silverman BL; Sullivan MA
Am J Addict; 2020 Jul; 29(4):313-322. PubMed ID: 32246728
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.
Gunderson EW; Sumner M
J Addict Med; 2016; 10(2):124-30. PubMed ID: 26918662
[TBL] [Abstract][Full Text] [Related]
11. Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.
Rosenblum A; Cruciani RA; Strain EC; Cleland CM; Joseph H; Magura S; Marsch LA; McNicholas LF; Savage SR; Sundaram A; Portenoy RK
J Opioid Manag; 2012; 8(6):369-82. PubMed ID: 23264315
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: A population-based cohort study in Ontario, Canada.
Iacono A; Wang T; Tadrous M; Campbell T; Kolla G; Leece P; Sproule B; Kleinman RA; Besharah J; Munro C; Doolittle M; Gomes T
Drug Alcohol Depend; 2024 Jan; 254():111032. PubMed ID: 38043224
[TBL] [Abstract][Full Text] [Related]
13. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
Sullivan JG; Webster L
Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
[TBL] [Abstract][Full Text] [Related]
14. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
[TBL] [Abstract][Full Text] [Related]
15. Repeated measures analysis of opioid use disorder treatment on clinical opiate withdrawal scale in a randomized clinical trial: sex differences.
Wang K; Shafique S; Xiao D; Walter SM; Liu Y; Piamjariyakul U; Xie C
J Addict Dis; 2024; 42(1):33-44. PubMed ID: 36655851
[TBL] [Abstract][Full Text] [Related]
16. Associations Between Buprenorphine\Naloxone and Methadone Treatment and non-Opioid Substance Use in Prescription-Type Opioid Use Disorder: Secondary Analyses From the OPTIMA Study: Associations entre le traitement avec la buprénorphine/naloxone et avec la méthadone et l'utilisation de substances non opioïdes dans le trouble lié à l'usage d'opioïdes de type sur ordonnance : analyses secondaires de l'étude OPTIMA.
Bakouni H; Sharafi H; Drouin S; Fortin R; Marsan S; Brissette S; Socias ME; Le Foll B; Lim R; Jutras-Aswad D
Can J Psychiatry; 2024 Apr; 69(4):252-263. PubMed ID: 37899716
[TBL] [Abstract][Full Text] [Related]
17. Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.
Roache JD; Pavlicova M; Campbell A; Choo TH; Peavy M; Kermack AS; Nunes EV; Rotrosen J
Alcohol Clin Exp Res; 2021 Dec; 45(12):2569-2578. PubMed ID: 34698397
[TBL] [Abstract][Full Text] [Related]
18. Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trial.
Gunderson EW; Hjelmström P; Sumner M;
Clin Ther; 2015 Oct; 37(10):2244-55. PubMed ID: 26412801
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine-naloxone Versus Buprenorphine for Treatment of Opioid Use Disorder in Pregnancy.
Perry BN; Vais S; Boateng JO; Jain M; Wachman EM; Saia KA
J Addict Med; 2022 Nov-Dec 01; 16(6):e399-e404. PubMed ID: 35916423
[TBL] [Abstract][Full Text] [Related]
20. Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.
Hassman H; Strafford S; Shinde SN; Heath A; Boyett B; Dobbins RL
Am J Drug Alcohol Abuse; 2023 Jan; 49(1):43-52. PubMed ID: 36001871
[No Abstract] [Full Text] [Related]
[Next] [New Search]